2023-01-25 04:18:00

Pacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Logo PR Newswire
PR Newswire

MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share. PacBio has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by PacBio. Before deducting the underwriting discount and estimated offering expenses payable by PacBio, PacBio expects to receive gross proceeds of approximately $175.0 million, assuming no exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about January 27, 2023 subject to satisfaction of customary closing conditions.

Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, Cowen and Company, LLC and Allen & Company LLC are acting as Joint Book Running managers for the offering.

PacBio intends to use the net proceeds from the offering for research and development, commercial infrastructure expansion and working capital and general corporate purposes. PacBio may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although it has no present commitments or agreements to do so.

PacBio filed a shelf registration statement relating to the shares of common stock with the Securities and Exchange Commission (the "SEC") on November 10, 2020, which became automatically effective upon filing and has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering with the SEC on January 24, 2023. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC and will be available on the SEC's website. When available, copies of the final prospectus supplement and the accompanying prospectus may be obtained from:

Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: (866) 471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, telephone: (866) 718-1649 or by emailing prospectus@morganstanley.com; or Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, telephone: (833) 297-2926 or by emailing Prospectus_ECM@cowen.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus.

About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing, and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not PacBio will be able to consummate the offering of common stock described herein, including due to the satisfaction of customary closing conditions and prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the proposed offering, PacBio and its business can be found under the heading "Risk Factors" in PacBio's most recent current, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC. PacBio assumes no duty or obligation to update or revise any forward-looking statements except as required by law.

Investors: Todd Friedman

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pacific-biosciences-of-california-inc-announces-pricing-of-upsized-public-offering-of-common-stock-301729994.html

SOURCE Pacific Biosciences of California, Inc.

Logo Nasdaq
Business / FinanceBy Mt Newswires2023-03-24 17:28:43
Health care stocks were higher Friday afternoon, with the NYSE Health Care Index rising 0.7%, the Health Care Select Sector SPDR Fund (XLV) up 0.9%, and the...

Logo EIN Presswire
HealthPress Release2023-03-24 09:38:32
Reports And Data Bioinformatics Market Size USD 11.45 Billion in 2022, CAGR of 14%, Market Trends advancements in genomes and proteomics research. The global...

Logo Nasdaq
Business / FinanceBy Bnk Invest2023-03-24 19:07:55
Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Walgreens Boots Alliance Inc (Symbol: WBA) were yielding...

Logo PR Newswire
NEW YORK, March 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BAC, TRKA, CS, DB, and RIOT.

Logo Nasdaq
Business / FinanceBy Fintel2023-03-24 20:30:54
Copa Holdings said on March 22, 2023 that its board of directors declared a regular quarterly dividend of $0.82 per share ($3.28 annualized). Previously, the...

Logo PR Newswire
HealthPress Release2023-03-24 15:02:00
LAS VEGAS, March 24, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and...

Logo Nasdaq
Business / FinanceBy Bnk Invest2023-03-24 14:39:42
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at...

Logo PR Newswire
TORONTO, March 24, 2023 /PRNewswire/ - SQI Diagnostics Inc. (the " Company " or " SQI ") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health...

Logo GlobeNewswire
TechnologyPress Release2023-03-24 12:03:00
WALL, N.J., March 24, 2023 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management (IAM) and...

Logo GlobeNewswire
SciencePress Release2023-03-24 11:00:00
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicines On track to submit IND for ONCR-021 in mid-2023 Preclinical data...

Logo Benzinga
Business / FinanceBy Business Wire2023-03-24 20:01:00
Karuna Therapeutics, Inc. KRTX ("Karuna"), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living...

Logo Nasdaq
TechnologyBy Zacks2023-03-24 15:30:48
It has been about a month since the last earnings report for United Therapeutics (UTHR). Shares have lost about 13% in that time frame, underperforming the...

Logo PR Newswire
HealthPress Release2023-03-24 15:35:00
New full-service offerings bridge critical resource gaps so all breast centers can offer risk-based cancer prevention and early detection at scale Chicago,...

Logo PR Newswire
SINGAPORE, March 24, 2023 /PRNewswire/ -- UOB was the sole lead manager and sole bookrunner for the National University of Singapore (NUS), as it priced a...

Logo Benzinga
Business / FinanceBy Lisa Levin2023-03-24 13:47:45
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday. Following the market opening Friday, the Dow traded down...

Logo The Business Journals
Technology2023-03-24 14:25:09
To date, the combined company has raised $50 million in total funding.

Logo Nasdaq
Business / FinanceBy Fintel2023-03-25 02:28:00
On March 24, 2023, Atlantic Equities downgraded their outlook for Block (NYSE:SQ) from Overweight to Neutral. Analyst Price Forecast Suggests 61.23% Upside...

Logo Nasdaq
Business / FinanceBy The Motley Fool2023-03-24 17:25:08
What happened Shares of Immuneering (NASDAQ: IMRX) were up 23.7% for the week as of early Friday afternoon, according to data provided by S&P Global...

Logo Inquirer.net
Business / FinanceBy Miguel R Camus2023-03-24 18:22:01
MANILA, Philippines -Alternergy Holdings Corp. completed the countrys first initial public offering (IPO) in 2023, raising P1.6 billion which will be mainly...

Logo PR Newswire
LISHUI, China, March 24, 2023 /PRNewswire/ -- Tantech Holdings Ltd (NASDAQ: TANH) ("Tantech" or the "Company"), a clean energy company in China, today...